The proteasome: A worthwhile target for the treatment of solid tumours?

This publication has 58 references indexed in Scilit:

• Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
  New England Journal of Medicine, 2005
• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
  British Journal of Haematology, 2004
• A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
  New England Journal of Medicine, 2003
• The proteasome: structure, function, and role in the cell
  Published by Elsevier ,2003
• The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
  Physiological Reviews, 2002
• Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
  Leukemia, 2000
• The 26S Proteasome Is Required for Estrogen Receptor-α and Coactivator Turnover and for Efficient Estrogen Receptor-α Transactivation
  Molecular Cell, 2000
• The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association
  Oncogene, 1999
• The ubiquitin-proteasome pathway: The complexity and myriad functions of proteins death
  Proceedings of the National Academy of Sciences, 1998
• Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation
  Leukemia, 1997